TRUVADA Drug Patent Profile

Which patents cover Truvada, and what generic alternatives are available?

Truvada is a drug marketed by Gilead and is included in one NDA.

The generic ingredient in TRUVADA is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Truvada

A generic version of TRUVADA was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8^th, 2017.

Summary for TRUVADA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	114
Clinical Trials:	231
Drug Prices:	Drug price information for TRUVADA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRUVADA
What excipients (inactive ingredients) are in TRUVADA?	TRUVADA excipients list
DailyMed Link:	TRUVADA at DailyMed

See drug prices for TRUVADA

See drug sales revenues for TRUVADA

Recent Clinical Trials for TRUVADA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	PHASE2
Yale University	PHASE2
PolyBio Research Foundation	PHASE2

See all TRUVADA clinical trials

Pharmacology for TRUVADA

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for TRUVADA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRUVADA	Tablets	emtricitabine; tenofovir disoproxil fumarate	100 mg/150 mg 133 mg/200 mg 167 mg/250 mg	021752	1	2017-05-19
TRUVADA	Tablets	emtricitabine; tenofovir disoproxil fumarate	200 mg/300 mg	021752	1	2008-09-26

US Patents and Regulatory Information for TRUVADA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-002	Mar 10, 2016	AB	RX	Yes	No
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-001	Aug 2, 2004	AB	RX	Yes	Yes
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-003	Mar 10, 2016	AB	RX	Yes	No

Expired US Patents for TRUVADA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-002	Mar 10, 2016
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-001	Aug 2, 2004
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-001	Aug 2, 2004

International Patents for TRUVADA

See the table below for patents covering TRUVADA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	170750
Austria	219366
Austria	270291

Supplementary Protection Certificates for TRUVADA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0513200	91073	Luxembourg		91073, EXPIRES: 20160131
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130
0513200	SPC/GB04/016	United Kingdom		PRODUCT NAME: EMTRICITABINE OR SALTS AND ESTERS THEREOF; REGISTERED: UK EU/1/03/261/001 20031024; UK EU/1/03/261/002 20031024; UK EU/1/03/261/003 20031024

TRUVADA (emtricitabine/tenofovir disoproxil fumarate) Market Dynamics and Financial Trajectory (U.S. and key markets)

Last updated: July 24, 2026

Truvada is a legacy HIV antiretroviral combination (emtricitabine 200 mg plus tenofovir disoproxil fumarate 300 mg) used for treatment and pre-exposure prophylaxis (PrEP). The product’s market dynamics are driven by (1) HIV incidence and adherence, (2) PrEP guideline adoption and persistence, (3) competitive displacement from newer PrEP regimens (notably Descovy and Apretude), and (4) U.S. generic erosion timing and uptake. Financial trajectory is defined by the shift from branded growth to revenue compression as PrEP competition and generic entry scaled.

---

What drives TRUVADA market demand: HIV treatment vs PrEP dynamics?

Truvada’s demand split is structurally anchored to two use cases: HIV-1 treatment and PrEP. The PrEP channel is the growth engine in most periods post-2012, but it is also the first to face displacement when alternative regimens expand.

How does PrEP eligibility and guideline adoption affect TRUVADA volume?

PrEP uptake depends on patient selection (risk level), clinician adoption, payer coverage, and adherence. Truvada is used for PrEP in populations where tenofovir DF is eligible. Uptake tends to be concentrated in insured settings and organized HIV prevention programs, with broader adoption following CDC/USPSTF guideline momentum.

Key demand variables:

• Incidence and risk group size: Higher new infections and higher-risk populations increase addressable demand.
• Adherence/persistence: PrEP benefit is adherence-linked. Discontinuation reduces effective demand.
• Payer controls: Prior authorization and step edits can slow switching.

How does HIV treatment usage affect resilience when PrEP faces competition?

HIV treatment demand is typically more stable than PrEP demand because switching depends on regimen efficacy, resistance history, tolerability, and payer/clinician protocols. Truvada used as part of many treatment combinations can retain baseline volume even when PrEP growth slows.

---

When does TRUVADA lose exclusivity and what is the generic entry risk?

Truvada is no longer protected as a fully exclusive branded product in the U.S. The core market inflection is generic entry and substitution in PrEP and treatment formularies. Once approved generics scale, branded pricing power collapses, and revenues shift toward limited remaining protected segments (if any) such as line extensions, dosage form specifics, or manufacturing/IP pockets.

What generic entry scenarios matter most for PrEP?

In PrEP, substitution can be faster because:

• prescribers and clinics often have standardized protocols,
• payers prefer lower-cost options,
• PrEP is preventive and adherence is monitored, so regimen continuity can be enforced administratively.

Generic exposure is typically most acute in insured populations where formularies control rapid switching.

What is the Orange Book status of TRUVADA that affects exclusivity?

The Orange Book provides the controlling legal status for drug product and patent claims. For Truvada, the practical effect is that branded exclusivity is limited and has largely given way to generic competition; remaining branded leverage, if any, typically comes from:

• specific patent claims tied to drug substance or formulation,
• manufacturing process constraints,
• and any last remaining blocking patents that delay specific generic launches.

(Orange Book-based analysis requires the current Orange Book record for each listed strength and manufacturer link, which is not provided in this request.)

---

Which competitors displace TRUVADA in PrEP: Descovy, Apretude, and long-acting options?

PrEP competition has progressively shifted from oral tenofovir DF regimens toward alternatives with improved safety, convenience, or broader targeting.

How does Descovy (emtricitabine/tenofovir alafenamide) compare with TRUVADA for PrEP uptake?

Descovy is a common oral alternative for PrEP where eligible. In practice, it competes where prescribers prefer tenofovir alafenamide (TAF) due to renal and bone safety considerations and where payer coverage supports it.

Effect on Truvada:

• reduces new PrEP starts,
• accelerates substitution in patients with renal risk factors who would otherwise select tenofovir DF,
• can slow growth even after generic erosion, because generics often follow branded trajectory but do not reverse volume declines.

How does Apretude (cabotegravir) change the competitive landscape?

Long-acting injectable PrEP reduces adherence burden tied to daily pills. That can produce a structural shift in patient flow, clinic protocol design, and payer contracting.

Effect on Truvada:

• decreases addressable oral PrEP starts,
• increases “switching” away from oral regimens when injection uptake is supported by clinics,
• can compress remaining branded volumes even after generics enter, because the injectable category expands.

Other oral PrEP options and how they affect TRUVADA’s share

Other oral regimens have varying eligibility and payer positioning. The key market dynamic is category migration: as newer options gain formulary adoption, Truvada’s share declines even when generics reduce cost.

---

What is the financial trajectory of TRUVADA revenue after PrEP growth: a trend map?

Without a current financial disclosure set or subscription dataset in this request, a precise quarter-by-quarter model is not feasible. What can be stated with decision-grade clarity is the directionality and drivers across phases:

Phase 1: Brand expansion (PrEP ramp)

• Revenue increases were tied to PrEP uptake and treatment use.
• Growth depended on guideline adherence and expanding clinical infrastructure.

Phase 2: Peak and plateau (PrEP competition begins)

• Competitors begin shifting starts.
• Payers and systems optimize formularies toward lower cost and preferred safety profiles.

Phase 3: Revenue compression from generic substitution

• Generic entry reduces net price.
• Branded revenue falls even if prescription count remains stable due to discounting and payer switching.

Phase 4: Residual demand and portfolio shift

• Remaining use concentrates in patients stable on regimen, specific clinical needs, or settings with constrained formulary switches.
• Brand accounting moves from growth to defending share.

---

How do U.S. payer behavior and contracting shape TRUVADA net pricing?

Net pricing declines typically reflect:

• increased rebate pressure as generics and alternative branded PrEP options expand,
• formulary placement adjustments,
• and contracting that favors least-cost alternatives.

What mechanisms drive price erosion faster than volume declines?

• annual contracting resets,
• rebate escalators tied to utilization,
• and step therapy that shifts new starts first, then continues to convert existing patients.

What mechanisms preserve volume longer than net price?

• fixed patient cohorts stable on regimen,
• resistance or tolerability constraints in HIV treatment,
• and clinic adherence programs that maintain continuity for preventive therapy.

---

What patent litigation affects TRUVADA generics and settlements?

In the U.S., the generic entry path typically follows the Paragraph IV framework when relevant patents are listed in the Orange Book. Litigation outcomes influence:

• whether generics enter earlier,
• whether settlements delay entry,
• and which strengths or label indications are covered.

For a litigation-and-settlement dossier, the request must include the active Orange Book patent list and the specific litigation docket references. Those records are not included here.

---

What formulations and manufacturing/IP barriers matter for TRUVADA’s competitive position?

Truvada’s competitive set is not driven by complex delivery systems. The barriers are primarily legal and manufacturing scale rather than device or combination technology.

Which strengths and dosage forms influence substitutability?

• The market is centered on oral tablets at set strengths.
• Switch speed depends on pharmacy stocking, clinician switching habits, and payer formularies.

How manufacturing and supply chain affect generic switching velocity

Even after approval, generic entrants can face:

• quality system ramp-up,
• supply allocation priorities,
• and cost-based competition that can determine how quickly market share converts.

---

Which markets outside the U.S. matter for TRUVADA revenue and how does exclusivity differ?

Global revenue mix depends on each country’s:

• approval and reimbursement cadence,
• generic tender processes,
• and how patent and regulatory exclusivities were applied.

How tenders and compulsory licensing practices can accelerate generic penetration

In many ex-U.S. markets, price controls and tendering can bring generics faster than in the U.S. That tends to compress revenue earlier but can sustain volume.

How treatment vs prevention public health programs change demand

Public HIV prevention programs support PrEP scaling in many countries. Program continuity can stabilize demand for oral regimens even when newer options appear, depending on budget and procurement rules.

(Exact country-level revenue split requires financial disclosures or country sales data that are not provided in this prompt.)

---

How does TRUVADA compare with Descovy and Apretude on market structure and growth risk?

Category shift risk

• Truvada faces share pressure from both oral TAF-based PrEP and long-acting injections.
• Generic availability reduces price but does not fully counter category migration if clinics and payers prefer non-DF regimens.

Brand resilience

• Brand resilience in PrEP typically weakens when injection options expand and when TAF regimens are preferred.
• In HIV treatment, regimen persistence is higher, but overall market for older backbone therapy can still stagnate as guidelines move to newer combinations or simplified regimens.

---

Key takeaways

• Truvada demand is driven by HIV treatment stability and PrEP growth, but PrEP is the first to be pressured by regimen innovation and payer/formulary switching.
• The long-term financial trajectory is dominated by generic substitution and contracting-driven net price erosion, not by sustained branded price or volume growth.
• Competitive displacement from Descovy and Apretude reduces new PrEP starts and slows oral regimen expansion even as generics lower costs.

---

FAQs

1. Why does TRUVADA’s PrEP market shrink faster than its HIV treatment market?
2. How do payer formularies determine whether patients stay on TRUVADA versus switch to Descovy?
3. What is the financial impact of long-acting cabotegravir PrEP adoption on oral tenofovir-based regimens?
4. Do generic TRUVADA launches typically target all strengths at once, or is rollout staggered?
5. What revenue metrics best track TRUVADA’s post-generic decline: prescriptions, net price, or total units?

---

References

1. CDC. Preexposure prophylaxis (PrEP) guidance and HIV prevention recommendations. (Accessed via CDC guidance pages).
2. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (TRUVADA product record).
3. U.S. FDA. Prescribing information and label information for TRUVADA, DESCOVY, and APRETUDE.
4. USPSTF. Preexposure prophylaxis for the prevention of HIV infection: clinical recommendations (current edition).

DrugChatter Q&A for TRUVADA

Truvada list price history?
Truvada patent expiration?
Truvada generic release date?
Truvada patent expiration generics cost goodrx?
Truvada patent expiration date?